Tharimmune (NASDAQ:THAR) Coverage Initiated at Rodman & Renshaw

Equities research analysts at Rodman & Renshaw assumed coverage on shares of Tharimmune (NASDAQ:THAR) in a research report issued on Friday,Benzinga reports. The firm set a “buy” rating and a $17.00 price target on the stock.

Tharimmune Stock Up 10.8 %

THAR stock opened at $2.25 on Friday. Tharimmune has a one year low of $1.84 and a one year high of $9.79. The firm has a 50-day moving average of $2.29 and a two-hundred day moving average of $2.99.

Hedge Funds Weigh In On Tharimmune

An institutional investor recently bought a new position in Tharimmune stock. Curi RMB Capital LLC bought a new stake in Tharimmune, Inc. (NASDAQ:THAR) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 23,620 shares of the company’s stock, valued at approximately $59,000. Curi RMB Capital LLC owned approximately 2.06% of Tharimmune as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 1.16% of the company’s stock.

Tharimmune Company Profile

Tharimmune, Inc, a clinical-stage biotechnology company, engages in the development of therapeutic candidates for rare, inflammatory, and oncologic diseases. The company's pre-clinical immuno-oncology pipeline includes TH104, a product candidate for the treatment of liver-related and other pruritogenic inflammatory conditions; TH3215 and TH0059 that are product candidates used to treat various solid tumors; and TH1940, which targets programmed cell death protein 1 (PD-1).